Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2006-11-21
2006-11-21
Saeed, Kamal A. (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C548S526000, C548S527000, C514S434000
Reexamination Certificate
active
07138426
ABSTRACT:
The present invention relates to compounds and derivatives thereof, their synthesis, and their use as estrogen receptor modulators. The compounds of the instant invention are ligands for estrogen receptors and as such may be useful for treatment or prevention of a variety of conditions related to estrogen functioning including: bone loss, bone fractures, osteoporosis, cartilage degeneration, endometriosis, uterine fibroid disease, hot flashes, increased levels of LDL cholesterol, cardiovascular disease, impairment of cognitive functioning, cerebral degenerative disorders, restenosis, gynecomastia, vascular smooth muscle cell proliferation, obesity, incontinence, and cancer, in particular of the breast, uterus and prostate.
REFERENCES:
patent: 5919814 (1999-07-01), Guillaumet et al.
patent: 6013607 (2000-01-01), Otten et al.
patent: WO 02/32373 (2002-04-01), None
patent: WO 02/32377 (2002-04-01), None
Powles, T.J. “Breast Cancer Prevention”, The Oncologist, vol. 7 (2002), pp. 60-64.
Park, W.C. and Jordan, V.C., “Selective estrogen receptor modulators (SERMS) and their roles in breast cancer prevention”, Trends in Moleecular Medicine, vol. 8, No. 2 (Feb. 2002) , pp. 82-88.
Wolff, A.C. “Use of SERMs for the Adjuvant Therapy of Early-Stage Breast Cancer”, Annals NY Academy of Sciences, vol. 949 (Dec. 2001), pp. 80-88.
Steiner, M.S., et al., “Selective Estrogen Receptor Modulators for the Chemoprevention of Prostate Cancer”, Urology, vol. 57 (Supplement 4A) (Apr. 2001), pp. 68-72.
Campisi, C., et al., “Complete resolution of breast cancer bone metastasis through the use of beta-Interferon and Tamoxifen,” Eur J Gynaecol Oncology, vol. 14, No. 6 (1993), pp. 479-483.
Ribeiro, G. and Swindell, R., “Adjuvant Tamoxifen for male breast cancer (MBC)”, Br. J. Cancer (1992), vol. 65, pp. 252-254.
Jordan, V.C., et al., “Selective Estrogen Receptor Modulation and Reduction in Risk of Breast Cancer, Osteoporosis, and Coronary Heart Disease”, Nat'l Cancer Inst., vol. 93, No. 19 (Oct. 2001), pp. 1449-1457.
Bjarnason, N.H., et al., “Six and twelve month changes in bone turnover are related to reduction in vertebral fracture risk during 3 years of raloxifene treatment in postmenopausal osteoporosis”, Osteoporosis Int. (2001), vol. 12, pp. 922-930.
Fentiman, I.S., et al., Tamoxifen Protects Against Steroid-induced Bone Loss:, Eur. J Cancer, vol. 28, No. 2/3(1992), pp. 684-685.
Rodan, G. A., et al., “Therapeutic Approaches to Bone Diseases”, Science (Sep. 2000), vol. 289, pp. 1508-1514.
Palomba, S., et al., “Effects of raloxifene treatment on uterine leiomyomas in postmenopausal women”, Fertility and Sterility, vol. 76, No. 1 (Jul. 2001), pp. 38-43.
Picard, F., et al., “Effects of the estrogen antagonist EM-652.HCl on energy balance and lipid metabolism in ovariectomized rats”, Int. Journal of Obesity (2000), vol. 24, pp. 830-840.
Badger, A.M., et al., “Idoxifene, a Novel Selective Estrogen Receptor Modulator, is Effective in a Rat Model of Adjuvant-Induced Arthritis”, Journ. of Pharmacol and Experimental Ther. (Dec. 1999), vol. 291, No. 3, pp. 1380-1386.
Goldstein, S.R., “The Effect of SERMs on the Endometrium”, Annals NY Academy of Sciences, vol. 949 (2001), pp. 237-242.
Goldstein, S.R., “Raloxifene Effect on Frequency of Surgery for Pelvic Floor Relaxation”, The American College of Obstet. and Gynecol., vol. 98, No. 1 (Jul. 2001), pp. 91-96.
Nuttal, M.E., et al., “Idoxifen: A Novel Selective Estrogen Receptor Modulator Prevents Bone Loss and Lowers Cholesterol Levels in Ovariectomized Rats and Decreases Uterine Weight in Intact Rats”, Endocrinology (Dec. 1998), vol. 139, No. 12, pp. 5224-5234.
Guzzo, J.A., “Selective Estrogen Receptor Modulators—a New Age of Estrogens in Cardiovascular Disease?”, Clin. Cardiol (2000), vol. 23, No. 1, pp. 15-17.
Simoncini, T. and Genazzani, A.R., “Direct vascular effects of estrogen and selective estrogen receptor modulators”, Curr. Opinion in Obstetrics and Gynecology (Jun. 2000), vol. 12, No. 3, pp. 181-187.
Yaffe, K., et al., “Cognitive Function in Postmenopausal Women Treated with Raloxifene”, N. Engl. Journal of Medicine, vol. 344, No. 16 (Apr. 2001), pp. 1207-1213.
Miller, et al., “Targeting the Estrogen Receptor ith SERMs”, Annual Reports in Medicinal Chemistry (2001), vol. 36, pp. 149-158.
Paige, et al., “Estrogen Receptor (ER) Modulators Each Induce Distince Conformational Changes in ED alpha and ER beta”, Proceedings of the National Academy of Sciences (Mar. 1999), vol. 96, No. 7, pp. 3999-4004.
Bendinskas, et al., “Sequence-Specific Photomodification of DNA by an Oligonucleotide-Phenanthrodihydrodioxin Conjugate”, Bioconjugate Chemistry (Sep. 1998), vol. 9, No. 5, pp. 555-563.
Blizzard Timothy Allen
DiNinno Frank P.
Morgan, II Jerry Dwain
Beeler Nicole M.
Daniel Mark R.
Merck & Co. , Inc.
Nolan Jason M.
Saeed Kamal A.
LandOfFree
Estrogen receptor modulators does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Estrogen receptor modulators, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Estrogen receptor modulators will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3648872